Since professors love to hear themselves talk, perhaps they recorded or will record their lecture notes. Play these through a voice-text conversion application.
A friend pointed me at retrofit bulk ink systems which totally eliminate the nasty little cartridges. The bulk ink containers are no more expensive than the Mfg. cartridge. Some initial investment which would pay off in fairly short order. Probably aimed at busy photographers, designers, etc. But might make sense for a busy average user. Go here:
http://www.mediastreet.com/cgi-bin/tame/mediastree t/n2.tam
Medscape is a highly regarded and very professional web site for medical professionals and laypeople. They have ongoing research on ADHD. This article specifically addresses Adolescent ADHD issues - I found no mention of NFT. This section (7) mentions alternate treatment for tic - A nonstimulant medication, atomoxetine (Strattera).
"Welcome Progress in the Diagnosis and Treatment of ADHD
Section 7 of 11
"Pharmacotherapy
"For most adolescents with ADHD, drug treatment is required to achieve and maintain a clinically significant reduction in core ADHD symptoms. Only a minority of adolescents with mild symptoms are able to cope successfully at school with academic interventions alone. Drug therapy should therefore be presented to both patients and parents as an essential tool with which to manage ADHD, not as a last resort
Stimulant medications are well established as the preferred first-line therapy for ADHD in all age groups. Methylphenidate (MPH), the most widely prescribed stimulant, is available in a number of formulations that differ in their duration of action (Table 3). The immediate-release formulation has a duration of action of only three or four hours and requires dosing two or three (sometimes four) times a day. Intermediate-acting and more recent longer-acting formulations require less frequent or once-daily dosing. Amphetamine-based treatments are also available in short-, intermediate-, and longer-acting formulations.
A nonstimulant medication, atomoxetine (Strattera), has recently been approved for use in children, adolescents, and adults with ADHD. It may be an appropriate second-line therapy for patients who fail to respond to stimulant therapy or who desire an alternative to stimulants. No well-controlled, prospective, long-term study has yet compared the safety and efficacy of atomoxetine with long-acting stimulant medications. []
Slashdot Mirror
...or gimme your lecture recordings.
Since professors love to hear themselves talk, perhaps they recorded or will record their lecture notes. Play these through a voice-text conversion application.
A friend pointed me at retrofit bulk ink systems which totally eliminate the nasty little cartridges. The bulk ink containers are no more expensive than the Mfg. cartridge. Some initial investment which would pay off in fairly short order. Probably aimed at busy photographers, designers, etc. But might make sense for a busy average user. Go here: http://www.mediastreet.com/cgi-bin/tame/mediastree t/n2.tam
Medscape is a highly regarded and very professional web site for medical professionals and laypeople. They have ongoing research on ADHD. This article specifically addresses Adolescent ADHD issues - I found no mention of NFT. This section (7) mentions alternate treatment for tic - A nonstimulant medication, atomoxetine (Strattera).
http://www.medscape.com/px/urlinfo
Free registration
jd
"Welcome Progress in the Diagnosis and Treatment of ADHD
Section 7 of 11
"Pharmacotherapy
"For most adolescents with ADHD, drug treatment is required to achieve and maintain a clinically significant reduction in core ADHD symptoms. Only a minority of adolescents with mild symptoms are able to cope successfully at school with academic interventions alone. Drug therapy should therefore be presented to both patients and parents as an essential tool with which to manage ADHD, not as a last resort
Stimulant medications are well established as the preferred first-line therapy for ADHD in all age groups. Methylphenidate (MPH), the most widely prescribed stimulant, is available in a number of formulations that differ in their duration of action (Table 3). The immediate-release formulation has a duration of action of only three or four hours and requires dosing two or three (sometimes four) times a day. Intermediate-acting and more recent longer-acting formulations require less frequent or once-daily dosing. Amphetamine-based treatments are also available in short-, intermediate-, and longer-acting formulations.
A nonstimulant medication, atomoxetine (Strattera), has recently been approved for use in children, adolescents, and adults with ADHD. It may be an appropriate second-line therapy for patients who fail to respond to stimulant therapy or who desire an alternative to stimulants. No well-controlled, prospective, long-term study has yet compared the safety and efficacy of atomoxetine with long-acting stimulant medications.
[]